Established in 2005 Sunny Pharmtech Inc. (Sunny) focused on the development of 505(b)(2) New Drug for cancer supportive care to improve the quality of life for cancer patients who are receiving the radiation or chemotherapy. More than 30 international patents were granted for this new application. Oral generic drug developments started in 2011. In 2014, the injectable team and API team were integrated into Sunny to strengthen the R&D capability. In 2017, the manufacturing facility at Longtan Science Park was constructed in compliance with PIC/S GMP. By integrating a team with expertise in all fields, the most advanced facilities, and great R&D achievements accumulated from previous years, Sunny has made herself a comprehensive pharmaceutical company. Furthermore, with vertical integration from API to Finished Drug Product in pharmaceutical value chain in chemistry, engineering, formulation, regulatory and project management categories has further made Sunny a specialty pharma with international market competitiveness .
Sunny is dedicated to developing 505(b)(2) New Drugs and specialty generic products based on the Quality-by-Design scheme. Focuses are mainly on niche injectable products, modified release generic and high barrier oral dosages.